Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% ...

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

The healthcare company said all doses will shift to a single monthly list price, cutting Wegovy’s price by about 50% and ...

Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.

Novo Nordisk is slashing the list prices of its flagship weight-loss and diabetes drugs, including Wegovy and Ozempic, by up ...

Click in for more news from The Hill {beacon} Health Care   The Big Story Novo Nordisk plans to slash GLP-1 prices The list ...

Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...

The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.

Novo Nordisk A/S NVO announced plans on Tuesday to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027. The price reduction will affect the obesity injection Wegovy, its ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, 2027, ...

Nova Ltd. (NASDAQ:NVMI) is among the 12 Best Tech Stocks that Beat Earnings Estimates. On February 13, 2026, Morgan Stanley ...

Nova Minerals Limited engages in the exploration of mineral properties in Australia and the United States. The company explores for gold, antimony, and critical minerals. It owns 85% interest in the ...